Reference health
A roadmap to precision medicine for multiple sclerosis
87/87 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 87 checked references that resolve
resolves10.1002/ana.22366
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
resolves10.1002/ana.21640
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
resolves10.3111/13696998.2013.778268
The cost burden of multiple sclerosis in the United States: a systematic review of the literature
resolves10.1212/WNL.0000000000001608
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry
resolves10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
resolves10.1093/brain/awh641
Cortical demyelination and diffuse white matter injury in multiple sclerosis
resolves10.1093/brain/awm038
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
resolves10.1016/j.jns.2014.08.047
MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis
resolves10.1001/archneurol.2008.505
Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis
resolves10.1177/1352458515588781
Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis
resolves10.1212/WNL.0b013e31821e559d
Demographic and clinical characteristics of malignant multiple sclerosis
resolves10.1177/1352458511410343
The psychosocial and cognitive impact of longstanding ‘benign’ multiple sclerosis
resolves10.1212/01.wnl.0000253185.03943.66
Longitudinal follow-up of “benign” multiple sclerosis at 20 years
resolves10.1093/brain/awg081
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
resolves10.1111/j.1468-1331.2008.02241.x
Natural history of multiple sclerosis in a population‐based cohort
resolves10.1212/01.wnl.0000188880.17038.1d
The natural history of primary progressive MS in British Columbia, Canada
resolves10.1093/brain/112.1.133
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY
resolves10.1212/01.wnl.0000194259.90286.fe
Disability progression in multiple sclerosis is slower than previously reported
resolves10.1093/brain/112.6.1419
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY
resolves10.1212/WNL.0000000000000524
Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis
resolves10.1177/1352458510379245
A method for evaluating treatment switching criteria in multiple sclerosis
resolves10.1007/s40263-013-0068-8
Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic
resolves10.1111/j.1600-0404.1970.tb05808.x
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
resolves10.1177/1352458516657439
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
resolves10.1177/135245859900500409
The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment
resolves10.1177/1352458512451512
Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures
resolves10.1212/01.WNL.0000154521.40686.63
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis
resolves10.1177/1352458513501570
Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis
resolves10.1177/1352458508094398
Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study
resolves10.1016/j.apmr.2015.01.008
Self-Efficacy as a Longitudinal Predictor of Perceived Cognitive Impairment in Individuals With Multiple Sclerosis
resolves10.1371/journal.pone.0050718
Multiple Sclerosis Decreases Explicit Counterfactual Processing and Risk Taking in Decision Making
resolves10.1007/s00415-015-7853-x
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
resolves10.2196/mhealth.4269
A New App for At-Home Cognitive Training: Description and Pilot Testing on Patients with Multiple Sclerosis
resolves10.1371/journal.pone.0154335
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review
resolves10.1177/135245850000600602
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients
resolves10.1177/1352458510391837
Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis
resolves10.3174/ajnr.A1659
Regional White Matter Atrophy−Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data
resolves10.1056/NEJMp1604033
Biomarker Tests for Molecularly Targeted Therapies — The Key to Unlocking Precision Medicine
resolves10.1212/WNL.0000000000003144
Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis
resolves10.1002/ana.20703
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
resolves10.1177/1352458514568827
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
resolves10.1212/01.wnl.0000280576.73609.c6
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
resolves10.1074/mcp.M115.053256
Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis
resolves10.1212/WNL.0b013e31820d8b1d
Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome
resolves10.1371/journal.pone.0090509
Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event
resolves10.1212/NXG.0000000000000087
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies
resolves10.1177/1352458515574148
Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis
resolves10.1212/WNL.0b013e3181a0fe3f
Combination of CSF
<i>N</i>
-acetylaspartate and neurofilaments in multiple sclerosis
resolves10.1111/ene.12579
Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis
resolves10.1136/jnnp-2014-309827
The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up
resolves10.1212/WNL.0000000000001491
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
resolves10.1177/1352458514521887
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis
resolves10.1177/1352458515623365
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
resolves10.1212/WNL.0000000000004683
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
resolves10.1093/brain/awy154
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
resolves10.1002/acn3.638
Neurofilament light chain serum levels correlate with 10‐year <scp>MRI</scp> outcomes in multiple sclerosis
resolves10.1007/s00415-010-5863-2
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
resolves10.1016/0022-510X(95)00152-R
Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit
resolves10.1093/brain/awq035
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
resolves10.1177/1352458511433063
Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis
resolves10.1093/brain/awg147
Expression profiling identifies responder and non‐responder phenotypes to interferon‐β in multiple sclerosis
resolves10.1007/s00415-016-8053-z
Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients
resolves10.1002/ana.24429
A pharmacogenetic study implicates
<scp>
<i>SLC9a9</i>
</scp>
in multiple sclerosis disease activity
resolves10.1016/j.jneuroim.2010.10.038
Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments
resolves10.1002/ana.23880
Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis
resolves10.1177/1352458513509509
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy
resolves10.1002/ana.24286
Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy
resolves10.1212/WNL.0000000000002314
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
resolves10.1177/1352458515607651
PML risk stratification using anti-JCV antibody index and L-selectin
resolves10.1093/brain/awh467
Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T
resolves10.1023/A:1008903126315
Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson's disease
resolves10.1016/j.artmed.2015.06.004
Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients
resolves10.1186/1471-2377-11-67
Computational classifiers for predicting the short-term course of Multiple sclerosis
resolves10.1016/j.autrev.2006.02.012
A model for the comprehensive investigation of a chronic autoimmune disease: The multiple sclerosis CLIMB study
The 6 references without a DOI — listed, not checked
no DOI — not checkedToward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease
(The National Academies Collection: Reports funded by National Institutes of Health). Washington, DC: National Institutes of Health, 2011.
no DOI — not checkedbibr2-1352458519881558
no DOI — not checkedbibr55-1352458519881558
no DOI — not checkedbibr69-1352458519881558
no DOI — not checkedbibr78-1352458519881558
no DOI — not checkedRelevance of health literacy to precision medicine: Workshop in brief (The National Academies Collection: Reports funded by National Institutes of Health). Washington, DC: National Institutes of Health, 2016.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1177/1352458519881558"><img src="https://citestamp.com/citestamped/10.1177/1352458519881558/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1177/1352458519881558)